Double bottom in GILDWonderful double bottom pattern spotted in GILD. It hasn't broken out yet. This chart is for educational purposes only. Please consult your financial advisor before making any buy or sell decision.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1,035.15
0.09 EUR
5.13 B EUR
24.51 B EUR
1.24 B
About Gilead Sciences, Inc.
Sector
Industry
CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
FIGI
BBG000DZFZF7
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Gildgilead science is in parallel channel since last 6 years and forming bearish downward pattern.
This is not good as follow through for the long pole is missing.
Manage risks and Own profitsHere's a rotated Trade Box For GLD
PLease refere to old trade boxes to get a keymap or feel free to PM!
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GIS is featured.
Frequently Asked Questions
The current price of GIS is 85.42 EUR — it has decreased by −2.04% in the past 24 hours. Watch GILEAD SCIENCES DL-,001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HAN exchange GILEAD SCIENCES DL-,001 stocks are traded under the ticker GIS.
GIS stock has fallen by −5.80% compared to the previous week, the month change is a 8.64% rise, over the last year GILEAD SCIENCES DL-,001 has showed a 23.55% increase.
We've gathered analysts' opinions on GILEAD SCIENCES DL-,001 future price: according to them, GIS price has a max estimate of 118.71 EUR and a min estimate of 65.53 EUR. Watch GIS chart and read a more detailed GILEAD SCIENCES DL-,001 stock forecast: see what analysts think of GILEAD SCIENCES DL-,001 and suggest that you do with its stocks.
GIS stock is 2.08% volatile and has beta coefficient of 0.51. Track GILEAD SCIENCES DL-,001 stock price on the chart and check out the list of the most volatile stocks — is GILEAD SCIENCES DL-,001 there?
Today GILEAD SCIENCES DL-,001 has the market capitalization of 104.63 B, it has increased by 3.92% over the last week.
Yes, you can track GILEAD SCIENCES DL-,001 financials in yearly and quarterly reports right on TradingView.
GILEAD SCIENCES DL-,001 is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
GIS earnings for the last quarter are 1.81 EUR per share, whereas the estimation was 1.37 EUR resulting in a 32.02% surprise. The estimated earnings for the next quarter are 1.62 EUR per share. See more details about GILEAD SCIENCES DL-,001 earnings.
GILEAD SCIENCES DL-,001 revenue for the last quarter amounts to 6.78 B EUR, despite the estimated figure of 6.30 B EUR. In the next quarter, revenue is expected to reach 6.80 B EUR.
GIS net income for the last quarter is 1.13 B EUR, while the quarter before that showed 1.51 B EUR of net income which accounts for −25.32% change. Track more GILEAD SCIENCES DL-,001 financial stats to get the full picture.
Yes, GIS dividends are paid quarterly. The last dividend per share was 0.70 EUR. As of today, Dividend Yield (TTM)% is 3.46%. Tracking GILEAD SCIENCES DL-,001 dividends might help you take more informed decisions.
GILEAD SCIENCES DL-,001 dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 16, 2024, the company has 18.00 K employees. See our rating of the largest employees — is GILEAD SCIENCES DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GILEAD SCIENCES DL-,001 EBITDA is 11.99 B EUR, and current EBITDA margin is 45.96%. See more stats in GILEAD SCIENCES DL-,001 financial statements.
Like other stocks, GIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GILEAD SCIENCES DL-,001 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GILEAD SCIENCES DL-,001 stock shows the strong buy signal. See more of GILEAD SCIENCES DL-,001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.